In 2022, Farmak pharmaceutical company expanded its presence on international markets and exported more than 240 types of products to more than 30 countries.

As reported in the company's press release, during the specified period, "Farmak" in particular, shipped products to the countries of the EU, Central and South America, the CIS, the Middle East, and Asia.

The company clarified that in 2021 Farmak opened a representative office in Vietnam and an office in the UAE.

JSC Farmak is the Ukrainian pharmaceutical market leader based on the sales of medicinal products in monetary terms. The company has been established in 1925.

As a result of successfully passing inspections by British regulatory authorities, which lasted more than a year, the Ukrainian company registered two new products, which will now be sold in Great Britain. This drug is used during MRI (ex: magnetic resonance imaging) and a hormonal drug to stop bleeding. Also on this market is an anti-inflammatory pain reliever used in dentistry, which the "Farmak" company has sold in Great Britain since 2021.

As reported, Farmak plans to open a new factory in Barcelona and a multifunctional laboratory complex with an R&D center for developing and testing new medicines in Spain in 2024.

Farmak is the leader of the pharmaceutical market of Ukraine in terms of sales of medicinal products in monetary terms. The company has a pharmaceutical plant in Kyiv and a plant for producing active pharmaceutical ingredients in Shostka (Sumy region).

The company's product portfolio includes more than 450 medicines. Among the main directions are endocrinological, gastroenterological, cardiology, neurological, anti-cold, and other medicines. The company annually reinvests up to 90% of its profits in development. Today, Farmak products are represented in more than 40 countries of the EU, Central and South America, the CIS, the Middle East, Asia, etc.